Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 1/20 | 0.64 |
| ▸ | ME1 | P48163 | 1/20 | 0.64 |
| ▸ | ME3 | Q16798 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | GFER | P55789 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15968389 | 0.80 | TSHR (0.54) | MAPTKMT2AMEN1GFERALDH1A1 | |
| SCHEMBL25367264 | 0.79 | TSHR (0.60) | MAPTKMT2AMEN1GFERALDH1A1 | |
| SCHEMBL4379381 | 0.79 | TRPV1 (0.57) | MAPTKMT2AMEN1GFERALDH1A1 | |
| SCHEMBL3799394 | 0.79 | GFER (0.74) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL3794409 | 0.79 | ME2 (0.68) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL2820899 | 0.79 | KMT2A (0.74) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL3797901 | 0.78 | ME2 (1.00) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL8091444 | 0.78 | MEN1 (0.80) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL3796071 | 0.77 | MAPT (0.80) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL3799766 | 0.77 | GFER (1.00) | ME2ME1ME3MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-28 | — | — | US | disclosed |
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243352-A1 | METHODS FOR TREATING DIABETIC COMPLICATIONS WITH CARBAMOYLOXY ARYLALKANOYL ARYLPIPERAZINE COMPOUNDS | LIPG, DPP7, IAPP | ME2 2122/4885ME1 3207/4885ME3 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.